FONAR Announces Fiscal 2016 2nd Quarter And Six Months Financial Results
MELVILLE,
NEW YORK, February 9, 2016 - FONAR Corporation (NASDAQ-FONR), The Inventor of MR Scanning™, reported its fiscal 2016 second quarter results for the quarter and six month period ended December 31, 2015. FONAR is the first Company in the MRI industry to manufacture an MRI (Magnetic Resonance Imaging) scanner. FONAR's substantial list of patents include recent patents for its technology enabling full weight-bearing MRI imaging in all the gravity sensitive regions of the human anatomy, especially the brain, extremities, spine and cerebrospinal fluid (CSF) flow.
The Company's two industry segments are the management of Stand-Up® MRI (UPRIGHT® Multi-Position™ MRI) centers, and the development, manufacturing and servicing of the UPRIGHT® MRI. Its premier MRI product, the FONAR UPRIGHT® Multi-Position™ MRI scanner, is the world's only MRI scanner licensed under FONAR's multiple UPRIGHT® Multi-Position™ MRI patents to scan all the patient's body parts in their normal fully weight-bearing UPRIGHT® positions.
Financial Highlights
Net Revenues increased 8% for the fiscal 2016 second quarter ended December 31, 2015 to $18.4 million versus $17.1 million for the corresponding quarter one year earlier.
Net Revenues increased 3% to $36.0 million for the fiscal 2016 six month period ended December 31, 2015, from $35.1 million for the corresponding six month period one year earlier.
Net Income increased 19% to $4.1 million for the fiscal 2016 second quarter ended December 31, 2015 versus $3.5 million for the corresponding quarter one year earlier.
Net Income increased 13% to $7.6 million for the fiscal 2016 six month period ended December 31, 2015 versus $6.7 million for the corresponding six month period one year earlier.
Income from Operations for the fiscal 2016 second quarter ended December 31, 2015 increased 17% to $4.2 million, from $3.6 million for the corresponding quarter one year earlier.
Income from Operations increased 11% to $7.8 million for the fiscal 2016 six month period ended December 31, 2015, versus $7.0 million for the corresponding six month period one year earlier.
Diluted net income per common share available to common shareholders increased 33% to $0.53 for the fiscal 2016 second quarter ended December 31, 2015 versus $0.40 for the corresponding quarter one year earlier.
Diluted net income per common share available to common shareholders increased 22% to $0.96 for the fiscal 2016 six month period ended December 31, 2015 versus $0.79 for the corresponding six month period one year earlier.
Total assets at December 31, 2015 were $80.4 million, as compared to $76.4 million at June 30, 2015. Total current assets at December 31, 2015 were $48.7 million, as compared to $43.6 million at June 30, 2015.
Total liabilities at December 31, 2015 were $24.8 million, as compared to $25.7 million at June 30, 2015. Total current liabilities at December 31, 2015 were $19.0 million, as compared to $18.8 million at June 30, 2015.
Stockholder's equity at December 31, 2015 was $80.4 million, as compared to $76.5 million at June 30, 2015.
Cash and cash equivalents increased 37% to $13.0 million at December 31, 2015, from $9.5 million at June 30, 2015.
Management Discussion
Raymond V. Damadian, president and chairman of FONAR Corporation said, "While we are still concerned about the environment created under the Affordable Care Act, we have continued to grow our business consistently. This is because of the adherence to a business strategy that we have mastered which has made the difference."
Dr. Damadian continued: "Our business plan is to grow consistently and to always provide our customers with the most optimal service. Our FONAR UPRIGHT® Multi-Position™ MRI scanner is not only the most comfortable MRI for our customers but the results from the scanner are of the highest professional quality. In this current medical era, it doesn't get any better than this for our patients. The patient sits, watches TV comfortably and obtains a weight-bearing MRI of his problem. Physicians appreciate that it is going to be a scan that can 'SEE IT ALL'
and allow the doctor to optimize the TREATMENT OUTCOMES FOR THEIR PATIENT."
Significant Events
As reported on January 6, 2016, the Company reported that its subsidiary Health Management Company of America, LLC (HMCA) had begun managing Stand-Up MRI of Great Neck, located at 600 Northern Blvd., Great Neck, New York, bringing the total number of HMCA-managed centers to 25: 18 in New York and 7 in Florida. Twenty four (24) of the centers are equipped with the FONAR UPRIGHT® Multi-Position™ MRI. Last year, the 24 HMCA-managed sites provided $57.6 million (83%) of FONAR's $69.1 million in revenue.
On February 4, 2016, the television network ESPN ran a 30 For 30 series documentary on the 1985 NFL Chicago Bears that featured Dr. Scott Rosa and Jim McMahon. During the approximately five minute segment, Jim McMahon said he was thankful to Dr. Rosa's treatment. Dr. Rosa provided his patented IGAT™ (Image Guided Atlas Treatment™) that utilized FONAR's UPRIGHT® MRI examination of Jim McMahon to determine the percussion direction and percussion angle of his IGAT™ procedure. FONAR provided the UPRIGHT® Multi-Position™ MRI that for the
first time successfully detected and diagnosed Jim McMahon's health issues as originating in Jim's neck (not his brain) from malalignments of the craniocervical junction vertebra (C1 & C2) from prior football traumas. These malalignments were obstructing cerebrospinal fluid (CSF) flow into his brain and generating the increased intracranial pressure (ICP) that was adversely affecting his health. This enabled Jim's successful cervical realignment by Dr. Rosa's IGAT™ (traumaimagingfoundation.com/.com).
Dr. Damadian said: "We are proud that our FONAR UPRIGHT® MRI has made such a critical difference to NFL great Jim McMahon. We recommend our shareholders watch the 30 For 30 series documentary on the 1985 NFL Chicago Bears when it runs again on Friday, February 12, 2016 at 9 PM Eastern Time on ESPN2." Check your local listings.
About FONAR
FONAR, The Inventor of MR Scanning™, is located in Melville, NY, was incorporated in 1978, and is the first, oldest and most experienced MRI company in the industry. FONAR introduced the world's first commercial MRI in 1980, and went public in 1981. FONAR's stellar product is the FONAR UPRIGHT® MRI (also known as the Stand-Up® MRI), the only whole-body MRI that performs Position™ imaging (pMRI™) and scans patients in numerous weight-bearing positions, i.e. standing, sitting, in flexion and extension, as well as the conventional lie-down position.
The FONAR UPRIGHT® MRI often sees the patient's problem that other scanners cannot because they are lie-down and "weightless" only scanners. The patient-friendly UPRIGHT® MRI has a near-zero claustrophobic rejection rate by patients. As a FONAR customer states, "If the patient is claustrophobic in this scanner, they'll be claustrophobic in my parking lot." Approximately 85% of patients are scanned sitting while they watch a 42" flat screen TV.
FONAR has new works-in-progress technology for visualizing and quantifying the flow of cerebrospinal fluid (CSF) which circulates throughout the brain and vertebral column at the rate of 32 quarts per day. This imaging and quantifying of the dynamics of this vital life-sustaining physiology of the body's neurologic system has been made possible first by FONAR's introduction of the MRI and now due to this latest works-in-progress for quantifying CSF in all the normal positions of the body, particularly in its upright flow against gravity. The type of patient that will
benefit from this technology includes those with various types of dementia such as former NFL quarterback Jim McMahon.
FONAR's substantial list of patents includes recent patents for its technology enabling full weight-bearing MRI imaging on all the gravity sensitive regions of the human anatomy, especially the brain, extremities and spine. FONAR's UPRIGHT® Multi-Position™ MRI is the only scanner licensed under these patents.
UPRIGHT® and STAND-UP® are registered trademarks and The Inventor of MR Scanning™, Full Range of Motion™, Multi-Position™, Upright Radiology™, The Proof is in the Picture™, True Flow™, pMRI™, Spondylography™, Dynamic™, Spondylometry™, CSP™, and Landscape™, are trademarks of FONAR Corporation.
This release may include forward-looking statements from the company that may or may not materialize. Additional information on factors that could potentially affect the company's financial results may be found in the company's filings with the Securities and Exchange Commission.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
ASSETS
|
| |
December 31,
2015
|
June 30,
2015 *
|
Current Assets: |
|
|
Cash and cash equivalents
|
$ 12,954 |
$ 9,449 |
Accounts receivable – net
|
4,557 |
3,791 |
Accounts receivable - related party
|
60 |
- |
|
|
9,567 |
9,082 |
Management and other fees receivable - net
|
14,656 |
14,058 |
Management and other fees receivable – related medical practices – net
|
3,644 |
3,507 |
Costs and estimated earnings in excess of billings on uncompleted contracts
|
279 |
682 |
|
|
2,259 |
2,192 |
Prepaid expenses and other current assets
|
767 |
860 |
Total Current Assets
|
48,743
|
43,621
|
Deferred income tax asset
|
8,423 |
8,423 |
Property and equipment – net
|
12,277 |
12,901 |
|
|
1,767 |
1,767 |
Other intangible assets – net
|
8,348 |
8,950 |
|
|
864 |
830 |
| Total Assets |
80,422
================ |
$ 76,492
================ |
*Condensed from audited financial statements.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
LIABILITIES AND STOCKHOLDERS' EQUITY
|
| LIABILITIES |
December 31,
2015
|
June 30,
2015 * |
Current Liabilities:
|
|
|
Current portion of long-term debt and capital leases
|
$ 2,467 |
$ 2,490 |
Accounts payable
|
1,291 |
1,783 |
Other current liabilities
|
8,733 |
8,253 |
Unearned revenue on service contracts
|
4,700 |
4,187 |
Unearned revenue on service contracts – related party
|
55 |
- |
Customer deposits
|
1,501 |
1,938 |
Billings in excess of costs and estimated earnings on uncompleted contracts
|
255 |
142 |
Total Current Liabilities
|
19,002 |
18,793 |
|
|
|
Long-Term Liabilities:
|
|
|
Deferred income tax liability
|
510 |
510 |
Due to related medical practices
|
247 |
237 |
Long-term debt and capital leases, less current portion
|
4,475 |
5,699 |
Other Liabilities |
544 |
469 |
Total Long-Term Liabilities
|
5,776 |
6,915 |
Total Liabilities
|
24,778 |
25,708 |
*Condensed from audited financial statements.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts and shares in thousands, except per share amounts)
(Unaudited)
LIABILITIES AND STOCKHOLDERS' EQUITY (Continued)
|
STOCKHOLDERS' EQUITY:
|
December 31,
2015 |
June 30,
2015 *
|
Class A non-voting preferred stock $.0001 par value; 453 shares authorized at December 31, 2015 and June 30, 2015, 313 issued and outstanding at December 31, 2015 and June 30, 2015
|
$ — |
$ — |
Preferred stock $.001 par value; 567 shares authorized at December 31, 2015 and June 30, 2015, issued and outstanding - none
|
— |
— |
Common Stock $.0001 par value; 8,500 shares authorized at December 31, 2015 and June 30, 2015, 6,062 issued at December 31, 2015 and June 30, 2015; 6,051 outstanding at December 31, 2015 and June 30, 2015
|
1 |
1 |
Class B Common Stock (10 votes per share) $ .0001 par value; 227 shares authorized at December 31, 2015 and June 30, 2015, .146 issued and outstanding at December 31, 2015 and June 30, 2015
|
— |
— |
Class C Common Stock (25 votes per share) $.0001 par value; 567 shares authorized at December 31, 2015 and June 30, 2015, 383 issued and outstanding at December 31, 2015 and June 30, 2015
|
— |
— |
Paid-in capital in excess of par value
|
175,448 |
175,448 |
Accumulated deficit
|
(129,994 ) |
(136,349) |
Notes receivable from employee stockholders
|
(28 ) |
(32) |
Treasury stock, at cost - 12 shares of common stock at December 31, 2015 and June 30, 2015
|
(675)
|
(675)
|
Total Fonar Corporation Stockholder Equity |
44,752 |
38,393 |
Noncontrolling interests |
10,892 |
12,391 |
Total Stockholders' Equity
|
55,644 |
50,784
|
Total Liabilities and Stockholders' Equity
|
$ 80,422
================
|
$ 76,492
================ |
* Condensed from audited financial statements
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
|
| |
THREE MONTHS
ENDED DECEMBER 31,
|
| REVENUES |
2015
|
2014
|
|
|
$ 742 |
$ 375 |
Service and repair fees - net
|
2,280 |
2,499 |
Service and repair fees - related parties - net
|
28 |
28 |
Patient fee revenue, net of contractual allowances and discounts
|
7,786 |
6,629 |
Provision for bad debts for patient fee |
(3,270 ) |
(2,897 ) |
Management and other fees - net
|
8,958 |
8,613 |
Management and other fees–related medical practices – net
|
1,845 |
1,845 |
|
|
18,369 |
17,092 |
COSTS AND EXPENSES
|
|
|
Costs related to product sales |
564 |
237 |
Costs related to service and repair fees
|
447 |
474 |
Costs related to service and repair fees - related parties
|
5 |
5 |
Costs related to patient fee revenue
|
2,238 |
1,902 |
Costs related to management and other fees
|
5,597 |
5,180 |
Costs related to management and other fees - related medical practices
|
1,012 |
1,240 |
|
|
412 |
359 |
Selling, general and administrative
|
4,117 |
3,824 |
|
|
(248 ) |
273 |
|
|
14,144
|
13,494
|
Income From Operations
|
4,225 |
3,598 |
Interest expense |
(139) |
(172) |
Investment income |
58 |
60 |
Other Expense
|
— |
(2) |
Income Before Provision for Income Taxes and noncontrolling Interests |
4,144 |
3,484 |
Provision for Income Taxes |
40 |
29 |
Net Income |
4,104 |
3,455 |
Net Income - Noncontrolling Interests |
(611) |
(797) |
Net Income - Controlling Interests
|
$ 3,493
================ |
$ 2,658
================ |
Net Income Available to Common Stockholders |
$ 3,266
================ |
$ 2,485
================ |
Net Income Available to Class A Non-Voting Preferred Stockholders
|
$ 169
================ |
$ 129
================ |
Net Income Available to Class C Common Stockholders |
$ 58
================ |
$ 44
================ |
Basic Net Income Per Common Share Available to Common Stockholders
|
$ 0.54
================ |
$ 0.41
================ |
Diluted Net Income Per Common Share Available to Common Stockholders
|
$ 0.53
================ |
$ 0.40
================ |
Basic and Diluted Income Per Share - Class C Common |
$ 0.15
================ |
$ 0.12
================ |
Weighted Average Basic Shares Outstanding – Common Stockholders |
6,051
================ |
6,051
================ |
Weighted Average Diluted Shares Outstanding - Common Stockholders |
6,179
================ |
6,179
================ |
Weighted Average Basic Shares Outstanding – Class C Common |
383
================ |
383
================ |
Weighted Average Diluted Shares Outstanding – Class C Common |
383
================ |
383
================ |
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
|
| |
FOR THE SIX MONTHS
ENDED DECEMBER 31,
|
| REVENUES |
2015
|
2014
|
|
|
$ 760 |
$ 1,646 |
Service and repair fees - net
|
4,564 |
4,989 |
Service and repair fees - related parties - net
|
55 |
55 |
Patient fee revenue, net of contractual allowances and discounts
|
15,901 |
13,416 |
Provision for bad debts for patient fee
|
(6,778) |
(6,042) |
Management and other fees - net
|
17,786 |
17,351 |
Management and other fees–related medical practices – net
|
3,691 |
3,662 |
|
|
35,979 |
35,077 |
COSTS AND EXPENSES
|
|
|
Costs related to product sales
|
676 |
1,322 |
Costs related to service and repair fees
|
990 |
981 |
Costs related to service and repair fees - related parties
|
12 |
11 |
Costs related to patient fee revenue
|
4,466 |
3,801 |
Costs related to management and other fees
|
11,015 |
10,379 |
Costs related to management and other fees - related medical practices
|
2,070 |
2,609 |
|
|
849 |
756 |
Selling, general and administrative
|
7,892 |
7,403 |
|
|
169 |
779 |
|
|
28,139
|
28,041
|
Income From Operations
|
7,840 |
7,036 |
Interest expense
|
(289) |
(376) |
Investment income
|
107 |
122 |
Other Income (Expense)
|
1 |
(2) |
Income Before Provision for Income Taxes and noncontrolling Interests
|
7,659 |
6,780 |
Provision for Income Taxes
|
90 |
69 |
Net Income
|
7,569 |
6,711 |
Net Income - Noncontrolling Interests
|
(1,214) |
(1,518) |
Net Income - Controlling Interests
|
$ 6,355
================ |
$ 5,193
================ |
Net Income Available to Common Stockholders
|
$ 5,942
================ |
$ 4,856
================ |
Net Income Available to Class A Non-Voting Preferred Stockholders
|
$ 308
================ |
$ 251
================ |
Net Income Available to Class C Common Stockholders
|
$ 105
================ |
$ 86
================ |
Basic Net Income Per Common Share Available to Common Stockholders
|
$ 0.98
================ |
$ 0.80
================ |
Diluted Net Income Per Common Share Available to Common Stockholders
|
$ 0.96
================ |
$ 0.79
================ |
Basic and Diluted Income Per Share - Class C Common
|
$ 0.27
================ |
$ 0.22
================ |
Weighted Average Basic Shares Outstanding – Common Stockholders
|
6,051
================ |
6,050
================ |
Weighted Average Diluted Shares Outstanding - Common Stockholders
|
6,179
================ |
6,178
================ |
Weighted Average Basic Shares Outstanding – Class C Common
|
383
================ |
383
================ |
Weighted Average Diluted Shares Outstanding – Class C Common
|
383
================ |
383
================ |
FONAR™ Corporation
110 Marcus Drive
Melville, N.Y. 11747
Tel. 631-694-2929
Fax. 631-390-9540
Email sales@FONAR.com
Investor Information
Site Map
| Terms of Use-Our
Privacy Policy Use
Copyright © 2016 FONAR- All Rights Reserved |
